Polyethylene glycol (PEG) surface modification can make nanomaterials highly hydrophilic, reducing their sequestration in the reticuloendothelial system. In this study, polyamidoamine (PAMAM) dendrimers bearing gadolinium (Gd) chelates were PEGylated with different PEG-chain lengths, and the effects on paramagnetic and pharmacokinetic properties were evaluated. Specifically, Gd chelatebearing PAMAM dendrimers (generations 4 and 5; G4 and G5) were conjugated with two different PEG chains (2 kDa and 5 kDa; 2k and 5k). Long PEG chains (5k) on the smaller (G4) dendrimer resulted in reduced relaxivity compared to non-PEGylated dendrimers, whereas short PEG chains (2k) on a larger (G5) dendrimer produced relaxivities comparable to non-PEGylated G4 dendrimers. The relaxivity of all PEGylated or lysine-conjugated dendrimers increased at higher temperature, whereas that of intact G4 Gd-PAMAM dendrimer decreased. All PEGylated dendrimers had minimal liver and kidney uptake and remained in circulation for at least 1 hour. Thus, surface-PEGylated Gd-PAMAM dendrimers showed decreased plasma clearance and prolonged retention in the blood pool. Shorter PEG, higher generation conjugates led to higher relaxivity.
Dendrimers are unique synthetic polymeric macromolecules that are very monodispersed, therefore making their pharmacokinetic properties amenable to precise characterization. Dendrimers have the advantage of multiple surface functional groups that can be used to target or label the dendrimer for imaging and drug delivery. The interior space of dendrimers can be used to conjugate or encapsulate drugs. [1] [2] [3] [4] [5] [6] [7] For imaging, dendrimers can be labeled with a variety of imaging "beacons." For instance, dendrimers conjugated to fluorescent dyes have been used for fluorescent imaging. 3, 6 Dendrimers loaded with gold nanoparticles or conjugated to iodinated compounds have been studied for x-ray computed tomography imaging. 3, 6, [8] [9] [10] Dendrimers containing chelated gadolinium (Gd) can be used for magnetic resonance imaging (MRI). 3, 6, 10, 11 MRI applications of dendrimers are particularly appealing, because the dendrimer can be labeled with multiple Gd chelates, creating a strongly paramagnetic macromolecule with higher relaxivities on a molar basis than conventional chelates, due to slower molecular tumbling rates of large macromolecules. Most U.S. Food and Drug Administration-approved Gd chelates, such as [Gd-diethylenetriamine pentaacetic acid (DTPA) · H 2 O] 2-(gadopentetate dimeglumine, Magnevist; Berlex, Princeton, New Jersey), typically demonstrate relaxivities of 4-5 mM -1 s -1 in clinically relevant magnetic fields ranging from 0.3 to 7 T. 12, 13 Dendrimer-based MR contrast agents demonstrate enhanced relaxivity (20-30 mM -1 s -1 at magnetic fields ranging from 0.5 to 1.5 T), while displaying reduced plasma clearance and prolonged retention in the blood pool. 10, 11 This could have useful applications in the study of vessels for a variety of disease conditions (atherosclerosis, angiogenesis, inflammation, lymphatic imaging, among others). Gd chelate-labeled polyamidoamine (PAMAM) dendrimers are commonly proposed as imaging and drug delivery agents, because they demonstrate a relatively neutral charge and excellent solubility. However, such agents commonly are excreted via the kidneys, the liver, or both, thus reducing plasma concentrations. Moreover, the size of the dendrimer, the composition of its interior, and the surface charge also determine its overall biodistribution. 10, 11, [14] [15] [16] Polyethylene glycol (PEG) modification (PEGylation) of dendrimers could be a helpful addition, because PEGylation not only reduces the toxicity of the nanoparticles but also helps the molecule escape recognition by the reticuloendothelial system, 17 resulting in reduced plasma clearance, which could be helpful for imaging and drug delivery applications. 7, 17, 18 Early results suggest that PEGylation could be a useful modification of the dendrimer 19, 20 ; however, systematic studies have not yet characterized the length of PEGylation, size of dendrimer, and the effects on relaxivity and clearance. Previous PEGylated Gd dendrimers were prepared by conjugating both PEG and Gd chelate to the terminal groups of the dendrimers. 19, 20 PEG was attached to some termini, and Gd chelate was attached to others. However, it is possible that this preparation method interfered with the uniformity of the dendrimers. Kono et al designed a fully PEGylated dendrimer conjugating other compounds [21] [22] [23] that improved homogeneity. Thus, PEGylation may have the desirable features of reduced toxicity and improved retention in the circulation with decreased rates of nonspecific renal and hepatic uptake. However, before this can be shown to be effective, the effects on relaxivity of dendrimer-based MRI contrast agents must be examined.
In this study, fully PEGylated PAMAM dendrimers loaded with Gd-DTPA were prepared. Lysine (Lys) was attached before the PEG modification for conjugation of Gd-DTPA to the side chain. As a control, non-PEGylated acetylated Lys-conjugated PAMAM dendrimer was used. To investigate the influence of the dendrimer generation as well as the PEG chain length, the following compounds were synthesized: PEG2k-PAMAM (G4), PEG5k-PAMAM (G4), and PEG2k-PAMAM (G5) ( Figure 1 ). Proton nuclear magnetic relaxation dispersion ( 1 H NMRD) and temperature-dependent relaxivities were examined, and in vivo dynamic MRI of mice injected with these agents was performed.
Methods

Materials
PEG2k-PAMAM (G4), PEG5k-PAMAM (G4), PEG2k-PAMAM (G5), and Ac-PAMAM (G4) [PAMAM (G4) bearing acetylated Lys] loaded with Gd-DTPA were synthesized by methods reported elsewhere. 18 Gd chelation was performed as described elsewhere. 19, 24, 25 The determination of Gd loading was performed by inductively coupled plasma optical emission spectroscopy, according to the manufacturer's instructions (SPS7800; SII NanoTechnology Inc., Chiba, Japan). The gel permeation chromatography (GPC) system (TSKgel G3000PW and G4000PW; Tohso Corp., Japan) had differential refractive index detection (RI-930; Jasco Inc., Japan). Dendrimers were eluted with 10 mM phosphate buffer containing 0.2 M sodium sulfate (pH 7.4) at 0.5 mL·min -1 at 30°C. The PEG with different molecular weight was used as a standard. The hydrodynamic diameters were estimated according to our previous report. 26 Relaxivity 1 H NMRD was measured by a custom-designed variable field T1-T2 analyzer (Southwest Research Institute, San Antonio, Texas), as described. 25 Briefly, the field strength was varied from 0.035 to 1.5 T (1.5-62 MHz) at 23°C. Solutions of PEGylated and non-PEGylated dendrimers with Gd-DTPA [PEG2k-PAMAM (G4), PEG5k-PAMAM (G4), PEG2k-PAMAM (G5), and Ac-PAMAM (G4)] (1 mM Gd, PBS, pH 7.4) were prepared. Additional measurements were performed at 0.8-T field strength (35 MHz) by changing the temperature to 16°C, 23°C, and 37°C.
Animals
Dynamic contrast-enhanced MRI was performed as described elsewhere. 25 Mice (n = 3 in each group) were chemically restrained with 2% isoflurane (Abbott Laboratories, Princeton, New Jersey), and O 2 was delivered using a Summit Anesthesia Solutions vaporizer (Bend, Oregon) at a flow rate of 0.8 L/min. Respiration rate was maintained at 25-30 respirations per minute and monitored using a Biopac System MP150 (Biopac Inc., Goleta, California). A tail vein cannula consisting of a 30-gauge needle attached to Tygon tubing (0.01 inch internal diameter) was then established. Before injection of the contrast agent, a T1 map was obtained by using a three-dimensional T1 fast field echo image sequence at two different flip angles (repetition time/ echo time 15.1/1.98 msec; flip angles 5 degrees and 24 degrees; water fat shift 2.508 pixels; acquisition matrix size 472 × 236 × 40; reconstruction matrix size 512 × 512 × 40; voxel resolution 170 × 170 × 600 μm; slice thickness 0.6 mm; two averages; scan time about 2 minutes). One hundred microliters of PEGylated and non-PEGylated Gd dendrimers [PEG2k-PAMAM (G4), PEG5k-PAMAM (G4), PEG2k-PAMAM (G5), and Ac-PAMAM (G4)] were injected (0.03 mmol Gd per kilogram) into the tail vein. The temperature of the mouse was maintained at 32°C using a Polyscience Model 210 heating recirculator with 3M Fluorinert Electronic Liquid FC-77, and body temperature was monitored using FOT-M fiberoptic sensors (Fiso Technologies Inc., San Jose, California) and a UMI-8 multichannel instrument (Fiso Technologies Inc.). All dynamic contrastenhanced MR images were obtained at 3 T (Achieva; Philips Medical Systems, Best, the Netherlands) with a 1-inch round receive-only modified saddle coil. A region of interest was placed on the kidney, the liver, and the jugular vein, and timeintensity curves were obtained. In addition, the single-slice data were processed into three-dimensional images with the maximum-intensity projection method. All animal experimental procedures were carried out in compliance with the Institute of Laboratory Animal Resources, "Guide for the Care and Use of Laboratory Animals," 27 National Research Council, and approved by the local Animal Care and Use Committee.
Results
Preparation of PEGylated dendrimer-based MR contrast agents
Three kinds of PEGylated PAMAM dendrimers bearing Lys (Z), PEG2k-PAMAM (G5), PEG5k-PAMAM (G4), and PEG2k-PAMAM (G4), and a non-PEGylated dendrimer, PAMAM (G4) bearing acetylated Lys, Ac-PAMAM (G4), were synthesized. It was shown that essentially all amino groups of the PAMAM dendrimer were modified with Lys(Z) [or acetylated Lys(Z)] and PEG. Then, DTPA with p-isothiocyanatobenzyl group was attached to the ɛ amino group of Lys of these four dendrimers after the deprotection of the Z group, as described. 18 About 30% of the amino groups were reacted with bifunctional DTPA. 18 Finally, Gd (III) was chelated to these dendrimers (Figure 1) . The Gd content of these dendrimers were estimated by inductively coupled plasma optical emission spectroscopy, indicating that Gd ions were chelated to essentially all DTPA molecules. These dendrimers were analyzed by GPC, and the data are displayed in Table 1 . The theoretical molecular weights are also shown. The experimental values were much lower than predicted. This is probably because the dendrimer is a spherical, highly dense 25 molecule compared with the standard molecule, PEG. 26 The hydrodynamic diameters (Table 1) were estimated from the GPC data according to our previous report.
26 PEG2k -PAMAM (G5) and PEG5k-PAMAM (G4) were larger than PEG2k-PAMAM (G4) and the non-PEGylated Ac-PAMAM (G4) dendrimer.
Relaxivity of the PEGylated dendrimers
T1 relaxivity (Figure 2) shows frequency-dependent (Figure 2, A) and temperature-dependent (Figure 2, B) R1 values. Dendrimer relaxivity was about sixfold higher than Gd-DTPA, which is consistent with the previous reports. 11, 19, 25 The highest and lowest relaxivities in our synthesized dendrimers at 23°C were observed in PEG2k-PAMAM (G5) ( (Figure 3 ) with similar trends to R1, except for gradual increase in R2 values with increasing frequency. It is likely that the water accessibility of PEGylated dendrimers was different from the non-PEGylated PAMAM dendrimers, probably because accelerated motion of grafted PEG chains at high temperature facilitates access of water molecules to the Gd chelate inside the PEG chains. The larger (G5) PEGylated PAMAM dendrimer also had enhanced relaxivity because of slower rotation of the molecule.
MRI of mice injected with the PEGylated dendrimers
The compounds were injected into the tail vein of mice. MR images after injection with PEGylated and non-PEGylated dendrimers of the heart and kidneys of mice are shown in Figure 4 . The PEGylated dendrimers enhanced the heart and blood pool and demonstrated prolonged retention in the circulation for at least 1 hour; however, the non-PEGylated dendrimer showed decreasing enhancement of the major vessels over the same time interval. Essentially no differences were observed among the three types of PEGylated dendrimers regarding their pharmacokinetics. In the case of the nonPEGylated dendrimer, on the other hand, the kidney gradually enhanced as a result of renal clearance. The MR intensity plots of the blood pool, kidneys, and the liver validated imaging results ( Figure 5 ). Neither the PEGylated nor the non-PEGylated dendrimers demonstrated visible enhancement in the liver. The clearance rate from the blood pool was calculated from Figure 5 , A, and is shown in Figure 5 , C. The clearance rate of all PEGylated dendrimers was clearly lower than the non-PEGylated dendrimer. In summary, the in vivo imaging data indicate that PEGylated dendrimers demonstrate decreased plasma clearance and minimal trapping by the reticuloendothelial system. Despite a 2000-fold injected dose difference, this data was consistent with previous biodistribution results using indium-111 radiolabeled PEGylated dendrimers. 18 
Discussion
In this study we show that PEGylation of a Gd-labeled PAMAM dendrimer reduces the relaxivity and plasma clearance, and alters susceptibility to temperature. Although PEGylation reduces relaxivity by decreasing access to water, this effect can be recovered by using a larger dendrimer (G5 vs. G4) with inherently higher relaxivities due to slower molecular tumbling rates. The addition of PEG to a dendrimer prolongs retention in the vascular pool, a property that could be useful for vascular Figure 4 . Three-dimensional MR images of the heart and large vessels (top) and kidneys (bottom) of mice injected with (A) PEG2k-PAMAM (G5), (B) PEG5k-PAMAM (G4), (C) PEG2k-PAMAM (G4), and (D) Ac-PAMAM (G4) at 1 hour after injection. Only Ac-PAMAM (G4) shows decreasing intensity from the heart and vessels and enhancement in the kidney parenchyma (arrows).
imaging in atherosclerosis, cancer, and inflammatory disorders, as well as for improving drug delivery.
The central advantage of dendrimer PEGylation is prolonged circulation times. In vivo biodistribution has previously demonstrated this advantage of PEGylated dendrimers 18 ; however, this study is different in that substantially higher doses of Gd chelated to dendrimer were injected (as high as 2000 times), as compared with previous injections of indium-111. Despite the huge differences in injected dose, the current MRI data also show that the PEGylated dendrimers are retained in the blood, whereas the non-PEGylated dendrimer accumulated in the kidney, consistent with the previous report. 18 Previous reports suggested that to achieve stability in the blood pool, PAMAM dendrimers as large as G7 would be necessary; however, dendrimers of this size are more difficult to reliably synthesize and inevitably accumulate in the liver. 11, 24 By PEGylating smaller dendrimers, which are more readily synthesized, blood pool retention can be achieved without the disadvantages of using a higher generation dendrimers. 11, 19, 24 Therefore, a fully PEGylated dendrimer is a useful platform for designing MRI contrast agents or other nanosized drug carriers.
PEGylation has the disadvantage of reducing relaxivity. The relaxivity of Gd chelate compounds depends on the water exchange rate as well as molecular mobility. 25, 28, 29 The PEGylation may interfere with water access, reducing relaxivity. This can be compensated for by using a slightly larger dendrimer with reduced molecular mobility and thus higher relaxivity. Our results indicate that the shorter PEG2k chains produced only modest reductions in relaxivity. However, the longer PEG chain (5 kDa) clearly reduced both the R1 and R2 values of the molecule. The molecular weight, diameter, and T1 relaxivity of these dendrimers are shown in Table 1 . Even though PEG2k-PAMAM (G5) and PEG5k-PAMAM (G4) are similar in diameter, the T1 relaxivities were different, indicating the substantial effect of PEGylation on relaxivity. Between the dendrimers with the same PEG length [PEG2k-PAMAM (G5) and PEG2k-PAMAM (G4)], the larger dendrimer exhibited the higher relaxivity. This indicates that both the dendrimer size and the PEG length affected the relaxivity. Thus, among the compounds tested, PEG2k-PAMAM (G5) was the most effective contrast agent from the relaxivity point of view. Interestingly, although PEGylation did not strongly affect the 1 H NMRD patterns compared to non-PEGylated dendrimers, 25, [28] [29] [30] the temperaturedependent relaxivity was slightly different from non-PEGylated (G4) dendrimers, which showed higher R1 values at lower temperature. The non-PEGylated but Lys-conjugated dendrimer also showed a temperature profile similar to the PEGylated dendrimers, which exhibited high R1 values at higher temperature. In addition, our previous reports indicate that Lys-based dendri-grafts showed similar properties. 25 Lys-based dendrigrafts have inner terminal amines and a loose interior structure; therefore, some of the chelates were not exposed on the surface, which is similar to PEG-conjugated dendrimer-agents but different from conventionally prepared agents. In addition, the conjugated Lys on the surface might be responsible for this behavior. The side chain of Lys is 4-aminobutyl, so that all of the conjugated chelates may not be on the surface but instead inside the dendrimer or obscured by the PEG chain. As the chelate mobility increases with increasing temperature, water molecules would have greater accessibility to these "hidden" chelates, resulting in higher relaxivities.
In conclusion, we have prepared and characterized the paramagnetic characteristics and in vivo pharmacokinetics of PEGylated PAMAM Gd-DTPA labeled dendrimers with different generations of dendrimers and PEG lengths. The relaxivities of these dendrimers were about sixfold higher than Gd-DTPA chelates alone. The modification of short PEG chains of 2k to the PAMAM dendrimer minimally affected relaxivity, but longer PEG chains (5k) affected relaxivity more strongly. The PEGylated dendrimers were stably retained in the blood pool for at least 1 hour, whereas non-PEGylated dendrimers were rapidly excreted through the kidney. Although PEGylated dendrimers were originally developed as drug delivery systems, 21, 26 they may also hold potential as stand-alone diagnostic agents or together as theranostic agents. These kinds of functional nanoparticles have become more important for achieving personalized medicine.
